SCHEMBL8204443

SCHEMBL8204443

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)NC2c1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NAMPT P43490 7/20 0.48
KDM1A O60341 1/20 0.44
KIT P10721 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
HIF1A Q16665 1/20 0.42
GBA1 P04062 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8201517 0.87 GPR119 (0.47) GPR119KDM1AKDM4E
SCHEMBL14263457 0.82 CRBN (0.39) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL8224919 0.82 HDAC1 (0.57) GPR119HDAC1HDAC6NAMPTKDM1A
SCHEMBL12492338 0.81 MEN1 (0.43) HDAC1KDM4EMEN1MAPTKMT2A
SCHEMBL3987027 0.81 MEN1 (0.48) KDM4EMEN1MAPTKMT2ADDB1
SCHEMBL8207921 0.80 GPR119 (0.49) GPR119KDM1ADDB1CRBNJAK2
SCHEMBL8227847 0.80 HDAC1 (0.53) GPR119HDAC1HDAC6NAMPTKDM1A
SCHEMBL8214411 0.80 GPR119 (0.56) GPR119HDAC1HDAC6NAMPTKDM1A
SCHEMBL8218928 0.79 HDAC1 (0.56) GPR119HDAC1HDAC6NAMPTKDM1A
SCHEMBL8217831 0.78 HDAC1 (0.53) GPR119HDAC1HDAC6NAMPTKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof SCHERING CORPORATION 2008-03-27 US disclosed
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof SCHERING CORPORATION 2008-03-27 US disclosed
WO-2008033460-A2 TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS SCHERING CORPORATION (US) 2008-03-20 WO disclosed
WO-2008033465-A1 AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076750-A1 Azetidinone Derivatives and Methods of Use Thereof LIPC, CES1, ZDHHC20 GPR119 81/4885HDAC1 937/4885HDAC6 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.